Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

To join this study, you need to be at least 18 years old and have signed a form saying you understand the study and agree to take part. Your doctor will need to confirm that you are generally well enough to participate and can attend all the required appointments and tests.

Your cancer must be a type called gastroesophageal adenocarcinoma, and it must have spread to other parts of your body. Importantly, tests on your cancer tissue must show that you have specific markers present, known as HER2 and PD-L1. You should not have received any previous treatment for your cancer that has spread, although some earlier treatments for cancer that hadn't spread are allowed if they finished at least six months ago.

There are also some health checks you'll need to pass. For example, your blood tests for your liver, kidneys, and blood cells need to be within a healthy range. Your doctor will carefully review all these requirements with you to see if this study could be a good option.

If you join this study, you will receive a combination of three medicines: Zanidatamab, Pembrolizumab, and chemotherapy (mFOLFOX). This will involve regular visits to the hospital for treatment infusions and check-ups. The study is 'open-label,' meaning both you and your doctors will know which treatments you are receiving.

Throughout the study, you will have various tests and assessments to monitor your health, how the treatment is working, and to check for any side effects. These will include blood tests, imaging scans (like CT scans), and reviews of your general well-being. Researchers will also be looking at how the treatment impacts your quality of life. The total duration of your participation will depend on how you respond to the treatment and your health, but it will involve ongoing treatment and follow-up for a period of time.